[en] The presence of chronic liver diseases may drastically limit the use of anti-diabetic drugs. Chronic liver diseases increase insulin resistance, and in some risk groups promote the development of diabetes. Therefore, antidiabetic treatment should be adapted to the severity of liver disease. However, diabetes, notably when associated with obesity and dyslipidemia, participates in the development of nonalcoholic fatty liver disease and to steato-hepatitis that may progress to cirrhosis and hepatocellular carcinoma. Other relations between diabetes and chronic liver disease will be discussed in this article. Finally, the indications and limits of each anti-diabetic therapy group will be discussed according to the degree of liver damage.
Hickman IJ, Macdonald GA. Impact of diabetes on the severity of liver disease. Am J Med 2007;120:829-34. (Pubitemid 47451297)
Sherwin RS. Role of the liver in glucose homeostasis. Diabetes Care 1980;3:261-5. (Pubitemid 10078121)
Petrides AS, Vogt C, Schulze-Berge D, et al. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 1994;19:616-27. (Pubitemid 24066891)
* Gundling F, Schepp W, Schumm-Draeger PM. Hepatogenous diabetes in cirrhosis : Academic sport or a neglected disease. Exp Clin Endocrinol Diabetes 2012;120:469-71.
Greco AV, Mingrone G, Mari A, et al. Mechanisms of hyperinsulinaemia in Child's disease grade B liver cirrhosis investigated in free living conditions. Gut 2002;51:870-5. (Pubitemid 35408611)
Barthel A, Schmoll D. Novel concepts in insulin regulation of hepatic gluconeogenesis. Am J Physiol Endocrinol Metab 2003;285:E685-92. (Pubitemid 37176418)
Kim MG, Choi WC. Differential diagnosis of diabetes mellitus caused by liver cirrhosis and other type 2 diabetes mellitus. Korean J Hepatol 2006;12:524-9.
*Bianchi G, Marchesini G, Zoli M, et al. Prognostic significance of diabetes in patients with cirrhosis. Hepatology 1994;20:119-25. (Pubitemid 24196500)
Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure : part I. Diagnosis and evaluation. Am Fam Physician 2006;74:756.
* Gariani K, Philippe J, Jornayvaz FR. Diabète et stéatose hépatique non alcoolique. Rev Med Suisse 2012; 8:1211-4.
Luyckx FH, Lefèbvre PJ, Scheen AJ. Non-alcoholic steatohepatites : Association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab 2000;26:98-106. (Pubitemid 30307580)
Seirafi M, Negro F. Hépatite C et résistance à l'insuline. Rev Med Suisse 2008;4:1859-62.
Romero-Gómez M, Fernández-Rodríguez CM, Andrade RJ, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008;48:721-7.
Kawaguchi T, Ide T,Taniguchi E, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007;102:570-6. (Pubitemid 46328143)
Moucari R, Asselah T, Cazals-Hatem D, et al. Association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008;134:416-23.
Waeber G, Vollenweider P, Marques-Vidal PM. Hyperferritinémie associée au syndrome métabolique : une nouvelle cible thérapeutique? Rev Med Suisse 2013; 9:2002-7.
* Simcox JA, McClain DA. Iron and diabetes risk. Cell Metab 2013;17:329-41.
* Blendea MC, Thompson MJ, Malkani S. Diabetes and chronic liver disease : Etiology and pitfalls in monitoring. Clinical Diabetes 2010;28:139-44.
* Khan R, Foster GR, Chowdhury TA. Managing diabetes in patients with chronic liver disease. Postgrad Med 2012;124:130-7.
* Scheen AJ. Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease. Expert Opin Drug Metab Toxicol 2014;10:839-57.
Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646.
Scheen AJ, Paquot N. Metformin revisited : A critical review of the benefit/risk balance in «at risk» patients with type 2 diabetes. Diabetes Metab 2013;39:177-90.
Morita Y, Ueno T, Sasaki N, et al. Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes. Hepatogastroenterology 2005;52:1338-43. (Pubitemid 41390988)
Yamagishi S, Nakamura K, Inoue H. Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH). Med Hypotheses 2005;65:377-9. (Pubitemid 40744771)
Lutchman G, Modi A, Kleiner DE, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007;46:424-9. (Pubitemid 47344777)
* Itou M, Kawaguchi T, Taniguchi E, et al. Dipeptidyl peptidase-4 : A key player in chronic liver disease. World J Gastroenterol 2013;19:2298-306.
Graefe-Mody U, Rose P, Retlich S, et al. Pharmacokinetics of linagliptin in subjects with hepatic impairment. Br J Clin Pharmacol 2012;74:75-85.
Ohki T, Isogawa A, Iwamoto M, et al. The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. Scientific World Journal 2012;2012:496453.
* Armstrong MJ, Barton D, Gaunt P, et al. Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN) : Study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. Trial registration : clinicaltrials.gov NCT01237119.
Letiexhe MR, Scheen AJ, Gerard PL, et al. Insulin secretion, clearance, and action on glucose metabolism in cirrhotic patients. J Clin Endocrinol Metab 1993;77:1263-8. (Pubitemid 23345480)
Nygren A, Adner N, Sundblad L, et al. Insulin uptake by the human alcoholic cirrhotic liver. Metabolism 1985;34:48-52. (Pubitemid 15150415)
Kannampilly JJ. Role of continuous subcutaneous insulin infusion (insulin pump) in reducing blood glucose in four patients with type 2 diabetes and cirrhosis : A case series. Diabetes Technol Ther 2010;12:543-5.
Kupcova V, Arold G, Roepstorff C, et al. Insulin degludec : Pharmacokinetic properties in subjects with hepatic impairment. Clin Drug Investig 2014;34:127-33.
* American Diabetes Association. Standards of medical care in diabetes - 2014. Diabetes Care 2014; 37(Suppl. 1):S14-80.